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ABSTRACT
Histone modification regulates gene expression,
and one major regulatory step in this process is
the ability of proteins that recognize epigenetic
marks to recruit enzymes required to specify tran-
scriptional outcome. Here we show that BRD7 is
a component of hSWI–SNF complexes that inter-
acts with PRMT5 and PRC2. Recruitment studies
revealed that BRD7 co-localizes with PRMT5 and
PRC2 on ‘suppressor of tumorigenecity 7’ (ST7)
and retinoblastoma-like protein 2 (RBL2) promoters
in patient-derived B cell lines, and that its associ-
ation with these target genes correlates with
hypermethylation of H3R8, H4R3 and H3K27.
Furthermore, inhibition of BRD7 expression
reduces PRMT5 and PRC2 recruitment to ST7 and
RBL2 promoters; however, only ST7 becomes tran-
scriptionally derepressed. Evaluation of the PRMT5-
and PRC2-induced epigenetic marks revealed that
while H3(Me2)R8, H4(Me2)R3 and H3(Me3)K27
marks are erased from the ST7 promoter,
demethylation of RBL2 promoter histones is incom-
plete. We also show that the arginine demethylase
(RDM) JMJD6, which can erase PRMT5-induced
H4R3 methylation, and the H3K27-lysine-specific
demethylases, KDM6A/UTX and KDM6B/JMJD3,
are differentially recruited to ST7 and RBL2.
These findings highlight the role played by BRD7
in PRMT5- and PRC2-induced transcriptional
silencing, and indicate that recruitment of specific
RDMs and KDMs is required for efficient transcrip-
tional derepression.
INTRODUCTION
Transcriptional silencing of tumor-suppressor genes is a
common trait of cancer cells, and it is known that there
are multiple regulatory steps that can inhibit gene expres-
sion. Epigenetic modiﬁcation of genomic DNA and
histones has been tightly linked to chromatin organization
and transcriptional regulation, and it has become
apparent that there are different classes of proteins
involved in the establishment, recognition and mainten-
ance, as well as removal of chromatin marks (1–5).
Extensive work has been done over the last decade to
characterize enzymes that can modify chromatin, but
little has been learned about factors involved in binding
histone epigenetic marks and their contribution to gene
regulation. One notable example that illustrates the im-
portance of proteins that bind epigenetically modiﬁed
histones is in the case of Trp-Asp repeat-containing
protein 5 (WDR5), a component of mixed lineage
leukemia (MLL) complexes, which binds dimethylated
H3K4 and facilitates its conversion to triply methylated
K4 (6–8). Besides the WD40 motif of WDR5, several
other domains have been identiﬁed in proteins that
exhibit high afﬁnity for epigenetically modiﬁed histones.
For instance bromodomain, a highly conserved 110 amino
acid region, has been shown to preferentially bind
acetylated histones and is believed to be involved in
mediating protein–protein interactions in both nuclear
and cytosolic compartments (9–13).
Among bromodomain-containing proteins that inﬂu-
ence gene regulation by promoting protein–protein inter-
actions is BRD7, which was initially identiﬁed through a
yeast two-hybrid screen as a protein that can interact with
the ﬁrst PDZ (Post-synaptic density protein [PSD95],
Drosophila disc large tumor suppressor [DlgA] and
zonula occludens-1 protein [zo-1]) domain of protein
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blot and in situ hybridization analyses showed that BRD7
is ubiquitously expressed in all tissues and at all mouse
embryonic stages. Moreover, immunoﬂuorescence experi-
ments indicated that BRD7 is localized predominently in
the nucleus, suggesting that it might play a role in sig-
naling events mediated by the PTP-BL multiprotein
complex (14). In a separate study, BRD7 was also
shown to interact with dishevelled-1 (Dvl-1) and
promote b-catenin and TCF4-induced transcription.
Further characterization of the BRD7-Dvl-1 interaction
indicated that BRD7 enhances Wnt signaling by
inducing glycogen synthase kinase-3b (GSK-3b)
dephosphorylation at tyrosine 216 and nuclear transloca-
tion of b-catenin (15). Therefore, based on these protein–
protein interaction studies, a model was proposed in
which BRD7 is believed to bring PTP-BL to the Dvl-1/
axin/APC/GSK-3b/b-catenin complex where it facilitates
GSK-3b dephosphorylation and promotes nuclear trans-
location of b-catenin.
In addition to BRD7, several transcription factors and
histone-modifying enzymes have been shown to contain
one or more copies of the bromodomain, and structural
studies have clearly demonstrated that bromodomain is a
chromatin-targeting module specialized in recognizing
acetylated histones (9,11,16). BRD7 can interact with the
four core histones, and deletion of its bromodomain
abolishes these interactions (17). Because BRD7 binds
active chromatin and positively inﬂuences Wnt signaling-
induced gene transcription, it is believed that its associ-
ation with target genes occurs only when genes are turned
on. However, recent reports have indicated that BRD7
can inhibit expression of E2F3, DP2 and MEK1 (18,19).
BRD7 has also been shown to be an integral component
of the BRG1-based hSWI–SNF chromatin remodeling
complex, and that it is involved in both target gene
activation as well as repression in embryonic stem cells
(20). Even though BRD7 has been implicated in target
gene repression, it is unclear how it contributes to this
process.
In this report, we show that BRD7 is a component of
PRMT5-containing hSWI–SNF complexes, and we also
show using a cell line that stably expresses His-tagged
BRD7 (His-BRD7) that subunits of the BRG1 and
BRM complexes are tightly associated with BRD7.
Interaction of BRD7 with PRMT5-containing hSWI–
SNF complexes was also conﬁrmed by glutathione
S-transferase (GST) pull-down assays. In addition, we
were able to determine that BRD7 is capable of interacting
with three core subunits of the polycomb repressor
complex 2 (PRC2) including SUZ12. To further under-
stand the relevance of these molecular interactions, we
evaluated recruitment of BRD7 and SUZ12 to known
PRMT5 and hSWI–SNF target genes. Chromatin
immunoprecipitation (ChIP) experiments revealed that
BRD7, SUZ12 and PRMT5 co-localize on ST7 and
retinoblastoma-like protein 2 (RBL2) promoters, and that
their association with these target tumor-suppressor genes
correlates with hypermethylation of H3R8, H4R3 and
H3K27 in patient-derived mantle cell lymphoma (MCL)
and chronic lymphocytic leukemia (CLL) cell lines.
Furthermore, when we evaluated the contribution of
BRD7 to PRMT5 and PRC2 target gene expression, we
found that inhibition of BRD7 expression results in loss of
PRMT5 and PRC2 recruitment as well as complete
removal of their epigenetic marks at the ST7, but not
RBL2 promoter. We have also determined that different
histone arginine demethylases (RDMs) and lysine-speciﬁc
demethylases (KDMs) are involved in transcriptional re-
activation of PRMT5 and PRC2 target genes, and that
their recruitment differs in a promoter speciﬁc manner.
MATERIALS AND METHODS
Plasmid DNA constructs
Plasmid pBABE-puromycin/His-BRD7 was generated by
ﬁrst subcloning a 1.9-kb BRD7 cDNA-encoding amino
acids 2–651, which was PCR-ampliﬁed from the
pCMV6-XL5/BRD7 vector (Origene Technologies Inc.)
using forward (50-CCGCTCGAGGGCAAGAAGCAC
AAGAAGCACAAG-30) and reverse (50-CCGCTCGAG
TCAACTTCCACCAGGTCCACACTC-30) primers
that incorporate a XhoI restriction site, into
XhoI-digested pET15b vector. Next, the His-tagged
BRD7 cDNA was excised out of pET15b/His-BRD7
vector as a ClaI-XbaI fragment and treated with klenow
before inserting into SnaBI-linearized pBABE-puromycin.
To generate plasmid pBABE-puromycin/Fl-BAF57, the
cDNA-encoding full-length BAF57 was PCR ampliﬁed
from pBS(KS
+)/BAF57, which was described previously
(21), using a forward primer (50-CCAGGAATTCATGT
CAAAAAGACC-30) that introduces an EcoRI restriction
site, and a reverse primer (50-CAGGAATTCCTCATTAT
TTGTCATCGTCGTCCTTGTAGTCTTGTTTTTTCT
CATCTTCTGGTATGGG-30) that introduces a ﬂag
epitope tag before a stop codon and EcoRI restriction
site. Next, the EcoRI-digested PCR fragment was
inserted into the corresponding site of pBABE-puromycin.
Plasmid pGEX-2TK/BRD7 (amino acids 2–651), which
expresses GST–BRD7 used in GST pull-down assays
and antibody production, was constructed by cloning a
SmaI-digested 1.9-kb fragment into SmaI-linearized
pGEX-2TK. Both forward (50-TCCCCCGGGGGGCA
AGAAGCACAAGAAGCACAAG-30) and reverse (50-T
CCCCCGGGTCAACTTCCACCAGGTCCACACTC
-30) primers used to amplify BRD7 (amino acids 2–651)
included a SmaI restriction site. Plasmids for in vitro ex-
pression of PRMT5, mSIN3A and hSWI–SNF subunits,
as well as pGEX-2TK/PAH2, which expresses GST fused
in frame with the mSIN3A paired amphipathic helix 2
(PAH2) (amino acids 300–404) have been described pre-
viously (21). To express MEP50 in vitro, plasmid
pBS(KS
+)/MEP50 was generated by inserting a 1-kb
EcoRI fragment, which was PCR-ampliﬁed from a
human peripheral blood cDNA library using forward
(50-CCGGAATTCGGCGTCCAGTTTGAGTCTAGGT
TG-30) and reverse (50-CCGGAATTCGGCAAAGAA
GTGGACACTCATGG-30) primers, into EcoRI-
linearized pBS(KS
+). Plasmid pBS(KS
+)/Fl-BRD7 was
constructed by inserting a 2-kb modiﬁed BRD7 cDNA
fragment, which was generated through a two-step
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 50bp of the PRMT5 50-UTR, into pBS(KS
+) cut with
XbaI. The ﬁrst PCR ampliﬁcation was carried out using a
50 primer (50-GTGGACAGCGCGAGGAGAAAGATG
ATGATGGGCAAGAAGCACAAGAAG-30), which
introduces 27nt of the PRMT5 50-UTR region
(underlined) upstream of the BRD7 start codon, and a
30 primer (50-GCTCTAGATCATTTGTCATCGTCGTC
CTTGTAGTCACTTCCACCAGGTCCACACTC-30)
designed to include a ﬂag-tag sequence followed by a
stop codon and an XbaI restriction site. To further
extend the 50-UTR region of BRD7, we conducted a
second PCR ampliﬁcation using a second 50 primer (50-G
CTCTAGAGTGATTGGCTACTAGTATCAAGGAAT
CCCGGCGTGGACAGCGCGAGGAGAAAG-30),
which incorporates an additional 32nt of the PRMT5
50-UTR (underlined) and an XbaI restriction site, and
the same 30 primer used above. Plasmids for in vitro ex-
pression of the PRC2 subunits, SUZ12, EED, EZH2 and
RBAp48 were derived from pFASTBAC vectors that were
described previously (22). Each cDNA was excised out of
the respective pFASTBAC vector and cloned into
pBS(KS
+). Plasmid pBS(KS
+)/SUZ12 was generated by
inserting a 2.2-kb EcoRI fragment into EcoRI-linearized
pBS(KS
+), pBS(KS
+)/EZH2 was constructed by inserting
a 2.25-kb BamHI fragment into BamHI-digested
pBS(KS
+), and pBS(KS
+)/RBAp48 was constructed by
ligating a 1.4-kb EcoRI–KpnI insert into pBS(KS
+)
digested with the corresponding restriction enzymes. To
induce EED protein expression in bacterial cells, plasmid
pGEX-2TK/EED was generated by inserting a 1.3-kb
PCR-ampliﬁed BamHI–EcoRI fragment, which encodes
EED amino acids 2–441, into pGEX-2TK cut with the
corresponding restriction enzymes. The full-length EED
cDNA sequence was ampliﬁed from pCMV6-XL5/EED
(Origene Technologies Inc.) using the following forward:
50-CGCGGATCCTCCGAGAGGGAAGTGTCGACT
GCG-30, and reverse: 50-CCGGAATTCTTATCGAAGT
CGATCGCAGCGCCA-30 primers. To produce
antibodies that recognize SUZ12, plasmid pGEX-2TK/
SUZ12 (amino acids 496–737) was constructed by
cloning a 0.7-kb SmaI–EcoRI fragment, which was
ampliﬁed using forward (50-TCCCCCGGGAGATGGC
TCCTATGCAGGAAAT-30) and reverse (50-CCGGAA
TTCTTGTTTTTTGCTCTGTTTTGAAAC-30) primers,
into SamI–EcoRI-linearized pGEX-2TK.
Cell culture and establishment of stable cell lines
HeLa S3, HeLa S3/Fl-BAF45, HeLa S3/Fl-BAF57 and
HeLa S3/His-BRD7 cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal
bovine serum (FBS). When Fl-BAF45, Fl-BAF57 and
His-BRD7 expressing cells were grown, puromycin was
added at ﬁnal concentration of 2.5mg/ml. Normal B cells
were isolated from tonsilar tissues obtained from
Children’s Hospital through the Cooperative Human
Tissue Network as described previously (23).
Transformed JeKo and WaC3CD5 cells were cultured in
RPMI-1640 supplemented with 10% FBS. To establish
HeLa S3/Fl-BAF57 and HeLa S3/His-BRD7 cell lines,
70–80% conﬂuent plates were incubated with 3ml of
retroviral supernatant harvested from Bing cells trans-
fected with either pBABE/Fl-BAF57 or pBABE/
His-BRD7 as described previously (24,25). After 2 days,
drug-resistant Fl-BAF57 and His-tagged BRD7 cells were
selected in the presence of 2.5mg of puromycin per milli-
liter. Several puromycin-resistant colonies were grown and
positive clones were identiﬁed by western blotting using
either anti-ﬂag (Santa Cruz) or anti-His (Covance, Inc.)
antibodies.
To generate WaC3CD5/shBRD7 cells, 5 10
6
WaC3CD5 cells were electroporated with 15mg of either
control shRNA or a cocktail of four BRD7 speciﬁc-
shRNA plasmids (QIAGEN), which contain BRD7
speciﬁc sequences, in 100ml of the appropriate reagent
using the Amaxa Biosystems nucleofector. Following
electroporation, cells were plated in 10ml of RPMI-1640
supplemented with 10% FBS, and 48h later puromycin
was added at a ﬁnal concentration of 2.5mg/ml. To select
individual clones that express low levels of BRD7,
electroporated cells were diluted to a ﬁnal concentra-
tion of 0.8 cell/100ml and plated in 96-well plates.
Puromycin-resistant clones were expanded in 6-well
plates and analyzed by western blotting and real-time
RT–PCR to determine the levels of endogenous BRD7.
Puriﬁcation of Fl-BAF45, Fl-BAF57 and His-BRD7
complexes
Flag tagged hSWI–SNF complexes were puriﬁed by
incubating 80mg of nuclear extract from either HeLa
S3/Fl-BAF45 or HeLa S3/Fl-BAF57 cells with 1ml of
anti-ﬂag M2 agarose beads as described previously (26).
To conﬁrm interaction of BRD7 with hSWI–SNF
complexes, 50mg of extract from His-tagged BRD7 cells
was incubated with 1ml of nickel–nitrilotriacetic acid (Ni–
NTA) agarose beads (QIAGEN) for 14h at 4 C in the
presence of 16U of micrococcal nuclease and 5mM
CaCl2. Extract from His-BRD7 cells was prepared by
lysing cells in RIPA buffer [50 mM Tris–HCl (pH 7.5),
250mM NaCl, 0.5% sodium deoxycholate, 1% NP-40,
0.1% SDS] and diluted 4-fold in buffer A [50 mM Tris–
HCl (pH 7.5), 10% glycerol, 2mM EDTA, 4mM DTT,
2mM PMSF] before incubating with Ni–NTA resin,
which was prepared by washing with 100mM NiSO4
solution followed by a wash with buffer B [12.5mM
Tris–HCl (pH 7.5), 62.5mM NaCl, 0.125% sodium
deoxycholate, 10mM imidazole, 0.25% NP-40, 0.025%
SDS]. Next, bound Ni–NTA beads were packed in a
column and the ﬂow through was collected and run
twice through the column before washing with buffer C
[20 mM HEPES–KOH (pH 7.9), 5mM MgCl2, 10%
glycerol, 0.5mM EDTA, protease inhibitors] supple-
mented with 500mM NaCl, followed by another wash
with buffer C containing 100mM NaCl and 8mM imid-
azole. Bound proteins were eluted in buffer C containing
100mM NaCl and 300mM imidazole, and fractions were
analyzed by sodium dodecyl sulfate (SDS)–8% polyacryl-
amide gel electrophoresis followed by either silver staining
or western blotting.
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To extract bulk histone from WaC3CD5 and WaC3CD5/
shBRD7 cells,  1 10
7 cells were washed twice with 10ml
of 1X PBS and resuspended in 1ml of TEB buffer
(137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM
KH2PO4, 0.5% Triton X-100, 0.02% NaN3,2 m M
PMSF). Samples were incubated on ice for 10min, and
cells were collected by centrifugation. Cell pellets were
washed with 0.5ml TEB buffer, resuspended in 250mlo f
0.2N HCl, and incubated at 4 C for 14h. Samples were
then centrifuged at 14000rpm for 10min at 4 C, and the
supernatants containing bulk histones were collected and
used to measure the levels of PRMT5- and PRC2-induced
methylation marks.
To show that interaction of BRD7 with hSWI–SNF
complexes is speciﬁc, nuclear extract from HeLa S3/
Fl-BAF45 cells and RIPA extract from HeLa S3/
His-BRD7 were incubated with either preimmune or
immune anti-CBP antibody essentially as described previ-
ously (27). After a 4-h incubation at 4 C, 65ml of a 50%
slurry of protein A agarose beads was added to each
sample, and the reaction mixtures were incubated at 4 C
for 14h. Beads were collected by centrifugation, washed
ﬁve times with 0.5ml of washing buffer [40 mM Tris–HCl
(pH 8.0), 180mM NaCl], and bound proteins were
analyzed by western blotting. When HeLa S3 RIPA
extract was incubated with either preimmune or immune
anti-BRD7 antibody, samples were treated as described
above and washed ﬁve times with 0.5ml of washing
buffer supplemented with 120mM NaCl, 0.5% NP-40
and 0.3% sodium deoxycholate. Next, bound endogenous
proteins were detected by western blot analysis.
Protein identiﬁcation by mass spectrometry and
western blot analysis
Protein mixtures puriﬁed by anti-ﬂag afﬁnity chromatog-
raphy were concentrated into a single 1-mm wide band by
electrophoresing through an SDS ‘4% stacking gel’ until
entering the ‘10% separating gel’. Next, the gel was
stained with Coommassie blue and the stacked band was
excised out. In-gel tryptic digests were subjected to a
micro-clean-up procedure on a 2-ml bed-volume of Poros
50 R2 reversed-phase beads, which was packed in an
Eppendorf gel-loading tip before samples were analyzed
using a QSTAR-XL hybrid quadrupole time-of-ﬂight
mass spectrometer (AB/MDS Sciex) equipped with a
NanoSpray ion source (AB/MDS Sciex) (28). Peptide
mixtures (in 20ml) were loaded onto a trapping guard
column (0.3 5-mm PepMap C18 100 cartridge from
LC Packings) using a Tempo nano MDLC system
(Applied Biosystems, Inc.) at a ﬂow rate of 20ml/min. A
detailed description of the capillary liquid chromatog-
raphy coupled to tandem mass spectrometry (LC–MS/
MS) analysis has recently been published (29).
Initial protein identiﬁcations from MS/MS fragment
ion data were done using the Mascot search engine
(Matrix Science, version 2.3.01) (30) and the NCBI
(National Library of Medicine, National Institutes of
Health) and IPI (International Protein Index, EBI,
Hinxton, UK) databases. One missed cleavage site is
allowed, precursor ion mass tolerance=0.4 Da,
fragment ion mass tolerance=0.4 Da, peptide modiﬁca-
tions are allowed for Met-oxide, Cys-acrylamide and using
signiﬁcance threshold score P<0.001. Unique peptide and
percent sequence coverages for all identiﬁed proteins are
exported to Excel for further analysis.
To visualize puriﬁed proteins, fractions containing
Fl-BAF45 or His-BRD7 complexes were separated on
an SDS–8% polyacrylamide gel and detected by western
blotting using enhanced chemiluminescence reagents ac-
cording to the manufacturer’s recommendations (GE
Healthcare). Antibodies raised against hSWI–SNF
subunits and PRMT5 have been described previously
(21,24,27). Anti-mSIN3A, anti-ﬂag, anti-JMJD6 and
anti-CBP antibodies were purchased from Santa Cruz,
and anti-His antibody was purchased from Covance.
Rabbit polyclonal antibodies raised against GST–BRD7
(amino acids 2–651) and GST–SUZ12 (amino acids 496–
737) were generated by Covance. Anti-H3(Me2)R8 and
anti-H4(Me2)R3 have been described previously
(23,27,31), while anti-H3(Me3)K27, anti-UTX were
purchased from Abcam. Anti-JMJD3 was purchased
from Millipore.
GST protein expression and pull-down assays
Expression of GST, GST-PAH2A, GST-BRD7 and
GST-EED was carried out essentially as described previ-
ously (32). Bacterial strains carrying pGEX-2TK plasmids
for expression of either GST or GST fusion proteins were
induced with 1.5mM IPTG for 4h at 37 C. To purify
induced proteins, 500mg of bacterial extract was incubated
with 30ml of a 50% slurry of GST beads on ice for 30min.
Bound GST beads were washed three times with buffer
STE-100 (20mM Tris–HCl [pH 7.6], 5mM MgCl2,
100mM NaCl, 1mM EDTA) supplemented with 0.5%
NP-40 and 1% bovine serum albumin (BSA), and
blocked for 4h at 4 C in 250ml of STE-100 containing
1mg of uninduced bacterial extract per ml, 1% BSA,
0.5% Carnation milk and 100mg of ethidium bromide
per ml. Next,
35S-labeled proteins were synthesized using
the TNT-coupled rabbit reticulocyte lysate as speciﬁed by
the manufacturer (Promega), and  9 10
4 cpm of each
in vitro-translated protein was incubated with immobilized
GST or GST fusion proteins at 4 C for 16h. Samples were
washed three times with 200ml of STE-100 supplemented
with 50mM NaCl, 1% BSA and 0.5% Carnation milk,
and twice with STE-100 before the retained proteins were
analyzed by SDS–polyacrylamide gel electrophoresis
followed by autoradiography.
ChIP and ChIP-re-ChIP assays
Cross-linked chromatin was prepared as described previ-
ously (21), except that after sonication, samples were
digested with 1 unit of MNase per milliliter at 37 C for
20min before adding 200ml of stop buffer [100 mM Tris–
HCl (pH 8.6), 0.45% SDS, 2.5% Triton X-100, 5mM
EDTA (pH 8.0), protease inhibitors]. Chromatin was
analyzed by agarose gel electrophoresis to ensure that
DNA fragment sizes do not exceed 500bp, and ChIP
assays were carried out as described previously (23,31).
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A sepharose beads, which were treated overnight with
blocking buffer (0.2mg of salmon sperm DNA per ml,
0.5mg of BSA per ml), before incubation with speciﬁc
antibodies. To amplify ST7, RBL2 and ST5 promoter se-
quences, pre-immune and immune antibodies were
incubated with pre-cleared chromatin from control and
transformed B cells at 4 C for 5h. Next, nucleoprotein
complexes were immunoprecipitated by adding
pre-blocked protein A sepharose beads at 4 C for 16h.
Samples were then washed extensively and bound nucleo-
protein complexes were eluted in 200ml of elution buffer
[50 mM Tris–HCl (pH 8.0), 10mM EDTA, 1% SDS] at
65 C for 20min. After elution, samples were incubated at
65 C for 12h to reverse cross-links, and treated with
buffer D (0.4mg of proteinase K per milliliter, 0.06mg
of yeast tRNA per milliliter) for 2h at 37 C, followed
by phenol and chloroform extraction. Samples were resus-
pended in 40ml of Tris–EDTA (pH 8.0) supplemented
with 0.2mg of RNase A/ml, and incubated at 37 C for
30min before performing real time PCR using the follow-
ing gene-speciﬁc primer sets and probes: ST7 (forward,
50-CCACTTGGCCTTCTCTTTC-30; reverse, 50-GGTCC
CTACAAGTGGCTTT-30; ABI probe, 50-6FAM-CCCTC
GCGTTCTGGGTCCATT-MGBNFQ-30), RBL2
(forward, 50-ATTTTTGGCCCCCTTGAA-30; reverse,
50-GCACCCGTAGTCTTGAGCAC-30; Roche universal
probe no. 3), ST5 (forward, 50-CGCCACGAAAGGTC
AGAG-30; reverse, 50-CTTAAGCTCCGATACCT
GCTG-30; Roche universal probe no. 17), GAS1
(forward: 50-GCGACAGTGAGCCTCTCC-30; reverse:
50-GATCTGGTCCCGCTCTCC-30; Roche universal
probe no. 77) and GAS2 (forward: 50-CTTTTCCTCCCC
ACGTATCC-30; reverse: 50-GGAGTAAAGAAGCACA
GGTCTTG-30; Roche universal probe no. 13).
For ChIP-re-ChIP assays, immunoprecipitated nucleo-
protein complexes were ﬁrst eluted twice with 75mlo f
elution buffer containing 20mM dithiothreitol (DTT) at
room temperature for 15min. The eluates were combined,
and 600ml of ChIP dilution buffer [100 mM Tris–HCl (pH
8.6), 5mM EDTA] was added to each sample. Next, the
second immunoprecipitation was conducted by adding the
appropriate antibody and pre-blocked protein A
sepharose beads. Samples were washed, and bound nu-
cleoprotein complexes were eluted and processed as
described above.
Reverse transcription (RT) real-time PCR
To measure the BRD7, ST7, RBL2 and ST5 mRNA
levels,  1mg of total RNA was reverse transcribed in a
20-ml reaction containing 2.5mM random hexamer primers
and Taqman Reverse Transciption reagents (Applied
Biosystems, Inc). Next, real-time-PCR was carried out
using the TaqMan system in a 10-ml reaction as described
previously (23). Primer sets and probes used to detect
BRD7 and its target genes were as follows: BRD7
(forward, 50-CAACCTATGGGGAAGACTCTG-30;
reverse, 50-TCTGCCATGACATACGGATAA-30; Roche
universal probe no. 89), ST7 (forward, 50-CCCCT AATT
GCTTCCTCTACC-30; reverse, 50-CCAAGAGAATATA
AGCAGTTGCAC-30; Roche universal probe no. 14),
RBL2 (forward, 50-TTGTTGGGTGCTTTTTATATAT
GC-30; reverse, 50-TTTCCATAAACTAAGTCCAAAGC
A-30; Roche universal probe no. 62) and ST5 (forward,
50-TTTTTGTGGCAGATAAGCTCAG-30; reverse, 50-G
GAGAAGGGGTAGAGCAAGG-30; Roche universal
probe no. 78). To normalize mRNA levels, we measured
the levels of 18S rRNA in both control and BRD7
knockdown cell lines using 1X pre-mixed 18S primer/
probe set (Applied Biosystems, Inc).
Statistical analysis
Results were expressed as the means±standard devi-
ations unless otherwise speciﬁed. Paired t-tests were used
to generate P-values for comparisons between two groups.
RESULTS
BRD7 is associated with PRMT5-containing hSWI–SNF
chromatin remodeling complexes
We have previously shown by mass spectrometry of indi-
vidually excised and stoichiometric gel bands that afﬁnity
puriﬁed ﬂag-tagged hSWI–SNF complexes contain
protein arginine methyltransferase PRMT5, and we have
also conﬁrmed this interaction by immunoprecipitation of
endogenous complexes puriﬁed by conventional chroma-
tography (21,27). To further characterize the subunit com-
position of hSWI–SNF complexes, protein mixtures
puriﬁed by anti-ﬂag afﬁnity chromatography were
concentrated into a single 1-mm wide band by
electrophoresing through an SDS–10% polyacrylamide
gel. After staining with Coomassie blue, the 1-mm wide
band was excised out and analyzed by mass spectrometry.
Protein identiﬁcation revealed that in addition to the
common BRG1 and BRM-associated factors (BAFs),
PRTM5-containing hSWI–SNF complexes puriﬁed from
two distinct HeLa cell lines, which express either
Fl-BAF45 or Fl-BAF57, included novel subunits such as
BRD7 (Supplementary Table S1).
In light of the recent ﬁndings, which show that BRD7 is
a bromodomain-containing protein capable of interacting
with the four core histones and is involved in transcrip-
tional repression of target genes (17,20), we sought
to examine and characterize its association with
PRMT5-containing hSWI–SNF complexes (Figure 1).
Nuclear extracts from either control HeLa S3 or HeLa
S3 cells that express Fl-BAF45 were incubated with
anti-ﬂag M2 afﬁnity gel, and after extensive washing the
retained proteins were eluted with a 20-fold molar excess
of ﬂag peptide. Consistent with the mass spectrometry
results, silver staining and western blot analysis of
afﬁnity-puriﬁed Fl-BAF45 complexes revealed the
presence of characteristic hSWI–SNF subunits such as
BRG1, BRM, BAF57, BAF45 and PRMT5 (Figure 1A
and B). Using a highly speciﬁc anti-BRD7 antibody, we
were able to conﬁrm the presence of BRD7 in puriﬁed
Fl-hSWI–SNF fractions but not in control HeLa S3 frac-
tions. When we tested for the presence of CREB-binding
protein (CBP), we were unable to detect it in
afﬁnity-puriﬁed Fl-BAF45 fractions. Similarly, when we
5428 Nucleic Acids Research, 2011,Vol.39, No. 13checked immunopuriﬁed anti-CBP fractions using
antibodies that can recognize BRG1, BRM, BRD7 and
PRMT5, there was no signal detected (Figure 1C),
indicating that association of BRD7 with hSWI–SNF is
speciﬁc.
To further verify interaction of BRD7 with
PRMT5-containing hSWI–SNF complexes, we estab-
lished a stable HeLa cell line that expresses His-tagged
(His) BRD7 and proceeded to afﬁnity-purify BRD7 and
its associated partners. Both silver staining and western
Figure 1. BRD7 co-puriﬁes with PRMT5-containing hSWI/SNF complexes. (A) Nuclear extracts from either control (Ctrl) HeLa S3 (lanes 1 and 2)
or HeLa S3/Fl-BAF45 cells (lanes 3 and 4) were puriﬁed by afﬁnity chromatography using anti-ﬂag M2 agarose beads, and 5ml of void and peak
fractions was analyzed by silver staining. (B) Western blot analysis was performed on 15ml of afﬁnity-puriﬁed control HeLa S3 (lane 2) and
ﬂag-tagged hSWI/SNF complexes (lane 3) using the indicated antibodies. The input lane shows expression of hSWI–SNF subunits in 20mgo f
HeLa S3/Fl-hSWI–SNF nuclear extract. (C) Nuclear extract (250mg) from HeLa S3/Fl-BAF45 cells was immunoprecipitated using either preimmune
(PI) (lane 2) or immune anti-CBP antibody (lane 3), and western blot analysis was conducted using the indicated antibodies. Input represents 20mgo f
HeLa S3/Fl-BAF45 nuclear extract. (D) RIPA extract from either control HeLa S3 or HeLaS3/His-BRD7 cells were incubated with Ni–NTA agarose
beads, and after extensive washing  15ml of afﬁnity-puriﬁed control HeLa S3 (lane 2) or His-BRD7 fraction (lane 3) was analyzed by western
blotting as described in (B). Input shows levels of BRD7-associated proteins in 20mg of HeLa S3 RIPA extract. (E) HeLa S3/His-BRD7 RIPA
extract was immunoprecipitated with either PI (lane 2) or anti-CBP antibody (lane 3), and proteins were detected by western blotting using the
indicated antibodies. (F) Approximately 250mg of HeLa S3 RIPA extract was immunoprecipitated with PI (lane 2) and immune anti-BRD7 antibody
(lane 3), and BRD7-associated proteins were detected by western blot analysis.
Nucleic Acids Research, 2011,Vol.39, No. 13 5429blot analysis showed that BRG1, BRM, BAF57, BAF45
and PRMT5 co-purify with His-BRD7 (Figure 1D, data
not shown). In stark contrast, BRD7 and hSWI–SNF
subunits were not detected in control HeLa S3 fractions.
Moreover, western blot analysis revealed that CBP was
absent in His-BRD7 afﬁnity-puriﬁed fractions, and that
components of hSWI/SNF were not detected in anti-
CBP immunoprecipitates (Figure 1D and E). These
results suggest that reciprocal interaction of BRD7 with
hSWI/SNF complexes is highly speciﬁc.
To rule out the possibility that interaction of BRD7
with PRMT5–hSWI–SNF complexes is not a direct
result of overexpressed subunits, we immunoprecipitated
endogenous BRD7 complexes and checked for the
presence of BRG1, BRM, SUZ12 and PRMT5
(Figure 1F). All four subunits were detected in anti-
BRD7 immunoprecipitates but not in control preimmune
fractions, suggesting that association of BRD7 with
hSWI–SNF and SUZ12 can be detected at the endogenous
level.
BRD7 directly interacts with hSWI–SNF subunits,
PRMT5 and MEP50
Having found that BRD7 co-puriﬁes with PRMT5-
containing hSWI–SNF complexes by afﬁnity chromatog-
raphy on two distinct columns, we wanted to ascertain the
speciﬁcity of their interaction by identifying the subunits
that mediate interaction with BRD7. GST pull-down
assays were carried out using bacterially expressed
GST-full length BRD7 and individually in vitro translated
hSWI–SNF subunits. When GST–BRD7 was incubated
with
35S-labeled hSWI–SNF subunits, BRG1, BRM,
PRMT5 and BAF60 were able to interact with BRD7,
but not with control GST or GST–PAH2A (Figure 2A).
A speciﬁc interaction was also observed between BRD7
and MEP50, a protein known for its ability to interact
with PRMT5 and components of the PRC2 complex (33).
Since BRD7 had previously been shown to interact with
the four core histones and we have found that it interacts
with MEP50, we examined whether BRD7 could interact
with components of the PRC2 complex. GST pull-down
assays showed that both SUZ12 and EZH2 speciﬁcally
interacted with GST–BRD7, while RBAp48 failed to
form a complex with BRD7 (Figure 2B). Because we
have been unable to express the fourth PRC2 subunit
in vitro, we generated a GST–EED fusion protein and
performed GST pull-down assays using in vitro translated
and
35S-labeled BRD7 (Figure 2C). As expected,
GST-immobilized EED was able to interact with compo-
nents of the PRC2 complex including SUZ12 and EZH2,
but not RBAp48. Similarly, GST–EED was also able to
interact with BRD7 suggesting that multiple interactions
occur between BRD7 and subunits of the PRC2 complex.
BRD7 co-localizes with PRMT5, PRC2 and their
epigenetic marks on ST7 and RBL2 promoters in
transformed lymphoma and leukemia cell lines
We have previously determined that PRMT5 is involved
in transcriptional repression of ST7 and RBL2 in trans-
formed B cells (23,31). To investigate the role played by
BRD7 in PRMT5 target gene expression and to further
explore the relationship between BRD7, PRMT5 and
PRC2, we monitored their proteins levels and recruitment
to the promoter region of known target genes in normal B
cells as well as transformed patient-derived MCL (JeKo)
and B-CLL (WaC3CD5) cell lines (Figure 3). Western blot
analysis revealed that while PRMT5 protein levels were
increased in transformed B cells, expression of SUZ12
and BRD7 proteins was unaffected (Figure 3A). When
we measured the levels of target genes, we found that
unlike ST5, expression of ST7 and RBL2 proteins was
signiﬁcantly reduced in JeKo and WaC3CD5 cells.
Consistent with our previous ﬁndings, ChIP experiments
showed that PRMT5 is enriched 4- to 9.7-fold at the ST7
and RBL2 promoters in both JeKo (P<10
 4 for ST7 and
P<10
 3 for RBL2) and WaC3CD5 (P<10
 3 for ST7 and
P=0.0018 for RBL2) cell lines compared to B cells
(Figure 3B and C). To determine if PRC2 and BRD7
are recruited to PRMT5 target genes, we assessed their
association with the ST7 and RBL2 promoters. When an
antibody that recognizes SUZ12, an integral component
of the PRC2 repressor complex, was used to
immunoprecipitate cross-linked chromatin from either
normal or transformed B cells, we noticed that there was
Figure 2. BRD7 can directly interact with hSWI/SNF and PRC2 com-
ponents. (A and B) Equal amounts (1–2mg) of GST, GST-PAH2 or
GST-BRD7 were immobilized on glutathione agarose beads, and
incubated with
35S-labeled hSWI–SNF and PRC2 subunits. After ex-
tensive washing the retained proteins were detected by autoradiog-
raphy. The input lane represents 10% of the total amount of protein
used in each reaction. (C) Similar amounts of GST, GST-PAH2 or
GST-EED were bound to glutathione agarose beads before adding
35S-labeled PRC2 subunits and BRD7. Samples were processed and
detected as described in A.
5430 Nucleic Acids Research, 2011,Vol.39, No. 13Figure 3. PRMT5, SUZ12 and BRD7 co-localize on ST7 and RBL2 promoters. (A) RIPA extracts from normal CD
19+ B cells or transformed JeKo
MCL and WaC3CD5 B-CLL cell lines were analyzed by western blotting using the indicated antibodies. Anti-b-ACTIN was used to show equal
loading. (B) Cross-linked chromatin from either normal B cells or transformed JeKo and WaC3CD5 cells was subjected to immunoprecipitation
using control PI, anti-PRMT5, anti-SUZ12 or anti-BRD7 antibody, and the immunoprecipitated DNA was analyzed by real-time PCR using primer
sets and probes speciﬁc for ST7 (amplicon 1: from –102 to+6) (B), RBL2 (amplicon 1: from –85 to –16) (C) and control ST5 (amplicon 1: from –118
to –59) (D). (E–G) ChIP assays were performed using either PI or immune antibodies that can speciﬁcally recognize PRMT5-induced methylation
marks, H3(Me2)R8 and H4(Me2)R3 or PRC2-induced H3(Me3)K27, and real-time PCR was performed to detect ST7, RBL2 and ST5 promoter
sequences as described in (B–D). Enrichment was measured as per cent of input. ChIP experiments were performed twice and PCR reactions were
carried out in triplicate.
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(P<10
 4 in JeKo and P<10
 3 in WaC3CD5) and
RBL2 (P<10
 4 in JeKo and P<10
 3 in WaC3CD5) pro-
moters in both transformed B cell lines compared to
normal B cells (Figure 3B and C).
Similarly, interaction of BRD7 with the ST7 and RBL2
promoters was enhanced 3- to 8-fold in JeKo (P=10
 3
for ST7 and P<10
 4 for RBL2) and WaC3CD5
(P=0.0265 for ST7 and P<10
 2 for RBL2) cell lines
compared to normal B cells (Figure 3B and C), indicating
that PRMT5, SUZ12 and BRD7 co-exist on common
target genes. To verify if association of PRMT5, SUZ12
and BRD7 is unique to ST7 and RBL2, we tested their
interaction with the promoter region of ‘ST50 (Figure 3D).
Real-time PCR analysis of immunoprecipitated DNA
showed that there was no enrichment of PRMT5,
SUZ12 and BRD7 at the ST5 promoter in both normal
and transformed B cells. To further conﬁrm our ﬁndings,
we evaluated recruitment of PRMT5, SUZ12 and BRD7
at different ST7, RBL2, and ST5 promoter sites using a
distinct set of primers (Supplementary Figure S1).
Consistent with our current results, recruitment of
PRMT5 was enhanced 2- to 5-fold (P<10
 3) at the ST7
promoter and 4.7- to 8-fold (P<10
 3) at the RBL2
promoter in both JeKo and WaC3CD5 cells. Similarly,
binding of SUZ12 was enriched 3- to 5-fold (P<10
 3)
and 6- to 13-fold (P<10
 4) at the ST7 and RBL2 pro-
moters, respectively. Interaction of BRD7 with target pro-
moters was also increased 3- to 5-fold (P<10
 4) at the
ST7 promoter and 3.5- to 7-fold (P<10
 3) at the RBL2
promoter, while association of all three chromatin binding
proteins with the ST5 promoter was unchanged. These
results indicate that enhanced association of PRMT5,
SUZ12 and BRD7 with the ST7 and RBL2 promoters is
highly speciﬁc.
We have already established that PRMT5 symmetrical-
ly methylates histone residues H3R8 and H4R3 at target
promoters, and we have also shown that methylation
of H3K4 is missing at these promoters (23,31). To
conﬁrm our previous ﬁndings, we measured the levels
of PRMT5-induced marks (Figure 3E–G). When
anti-H3(Me2)R8 and anti-H4(Me2)R3 antibodies were
used to evaluate the methylation status of promoter
histones H3 and H4, we found that methylation of
H3R8 was increased 11.5- to 15-fold (P=0.0044 in
JeKo and P<10
 3 in WaC3CD5), while methylation of
H4R3 was increased 8- to 9-fold (P<10
 4 in JeKo and
P<10
 3 in WaC3CD5) at the ST7 promoter in cancer
cells compared to normal B cells (Figure 3E).
Methylation of H3R8 and H4R3 was also enhanced 6-
to 7-fold at the RBL2 promoter in JeKo [P=0.0031 for
H3(Me2)R8 and P<10
 3 for H4(Me2)R3] and WaC3CD5
[P<10
 4 for H3(Me2)R8 and P=0.0024 for H4(Me2)R3]
cells (Figure 3F). Consistent with our results using the
anti-PRMT5 antibody, there was no enrichment of
PRMT5-induced epigenetic marks at the ST5 promoter
(Figure 3G). Because ChIP studies have shown that
SUZ12 is co-recruited to PRMT5 target genes, we
investigated whether the PRC2-induced H3(Me3)K27 epi-
genetic mark is enriched at the ST7 and RBL2 promoters
(Figure 3E–G). ChIP analysis showed that methylation of
H3K27 was enhanced 6-fold at the ST7 promoter
(P=0.0004 in JeKo and P=0.0002 in WaC3CD5), and
4- to 5-fold at the RBL2 promoter (P=0.0006 in JeKo
and P=0.0002 in WaC3CD5) in transformed B cells. No
signiﬁcant enrichment of methylated H3K27 was noticed
at the ST5 promoter.
To ensure that BRD7, PRMT5 and SUZ12 are re-
cruited to the same nucleosomes in the promoter region
of ST7 and RBL2 target genes, we performed ChIP-re-
ChIP experiments on cross-linked and MNase-treated
chromatin from transformed B cells (Figure 4). Our
ﬁndings indicate that when anti-PRMT5 is used ﬁrst to
immunoprecipitate chromatin from either JeKo or
WaC3CD5 cells, SUZ12 is associated with the
immunoprecipitated PRMT5 nucleoprotein complexes as
evidenced by its 6- to 13-fold enrichment at the ST7
(P=0.0058 for JeKo and P=0.0009 for WaC3CD5)
and RBL2 (P<10
 4 for both cancer cell lines) promoters
(Figure 4A and B). When the same experiment was carried
out using the anti-SUZ12 antibody ﬁrst, association of
PRMT5 with the ST7 (P=0.0002 for JeKo and
P<10
 4 for WaC3CD5) and RBL2 (P=0.0006 for
JeKo and P<10
 4 for WaC3CD5) promoters was
enhanced to the same extent (7- to 10-fold). More import-
antly, when we examined binding of BRD7 in combin-
ation with either PRMT5 or SUZ12, we found that
BRD7 is tightly associated with both proteins at the ST7
(6- to 8-fold enrichment, P<10
 4) and RBL2 (10- to
15-fold enrichment, P<10
 4) promoters. Analysis of
BRD7, PRMT5 and SUZ12 recruitment to the ST5
promoter region did not show any enrichment.
Collectively, these results indicate that BRD7, PRMT5
and SUZ12 physically co-exist in the promoter region of
target tumor suppressor genes.
Having found that BRD7 is in complex with
PRMT5-containing hSWI–SNF, we sought to evaluate
recruitment of one of its core subunits, BRG1, to
PRMT5 and SUZ12 target genes (Supplementary
Figure S2). BRG1 binding to the ST7 promoter was
increased 5- to 8-fold (P<10
 3), while its recruitment to
the RBL2 promoter was enriched 4- to 5-fold (P<10
 4)i n
transformed B cells. Consistent with its ability to interact
with BRD7 and PRMT5, interaction of BRG1 with ST7
and RBL2 promoters was enhanced to the same extent
using a second set of primers (Supplementary
Figure S2B and D). Moreover, there was no noticeable
change in BRG1 recruitment to the ST5 promoter.
These results suggest that BRG1–hSWI–SNF is recruited
to the same target promoters as PRMT5, SUZ12 and
BRD7.
BRD7 knockdown results in transcriptional derepression
of ST7 but not RBL2
To gain more insight into the role played by BRD7 in
epigenetic regulation of PRMT5 and PRC2 target genes,
we established WaC3CD5 stable cell lines where BRD7
levels were reduced via concomitant expression of four
BRD7-speciﬁc shRNAs, and measured the mRNA and
protein levels of PRMT5 and PRC2 target genes
(Figure 5). Real time RT–PCR showed that BRD7
5432 Nucleic Acids Research, 2011,Vol.39, No. 13mRNA was knocked down 50–60% in most WaC3CD5/
shBRD7 stable cell lines examined including clones 1
and 2 (P<10
 3), and western blot analysis revealed that
BRD7 protein levels were reduced 3- to 4-fold (Figure 5A
and B). We have previously shown that reducing expres-
sion of PRMT5 triggers transcriptional derepression of
ST7 and RBL2 in JeKo, Raji and WaC3CD5 cell lines
(23,31). Therefore, to determine if reduced expression of
BRD7 impacts transcription of PRMT5 and PRC2 target
genes, we measured the ST7 and RBL2 mRNA levels in
both control and BRD7 knockdown cells (Figure 5C and
D). Our results revealed that while ST7 is transcriptionally
derepressed 2–4-fold (P<10
 4) in WaC3CD5/shBRD7
stable cell lines clones 1 and 2, RBL2 mRNA levels are
unaffected, indicating that there are different molecular
determinants involved in their regulation. Furthermore,
when we measured the levels of ST7 and RBL2 proteins
in control and BRD7 knockdown cell lines clones 1 and 2,
we found that RBL2 protein expression was unaffected,
whereas expression of ST7 protein was suppressed
(Figure 5B), suggesting that there might be post-
transcriptional mechanisms involved in its regulation.
Recruitment of PRMT5 and SUZ12 to ST7 and RBL2
target promoters is compromised in BRD7 knockdown
cell lines
To uncover the underlying cause for the lack of RBL2
transcriptional derepression in BRD7 knockdown cells,
we considered the possibility that association of PRMT5
and SUZ12 with the RBL2 promoter might be preserved
in the absence of BRD7. Therefore, we carried out ChIP
experiments using cross-linked chromatin from control
WaC3CD5 and WaC3CD5/shBRD7 cells, and we also
examined the levels of PRMT5 and SUZ12 proteins as
well as their epigenetic marks (Figure 6). Western blot
analysis showed that expression of PRMT5, SUZ12 and
global levels of their induced methylation marks were un-
affected in BRD7 knockdown cells (Figure 6A). As
expected, recruitment of PRMT5, SUZ12 and BRD7 to
the ST7 promoter was enhanced 5.8- to 7.3-fold (P<10
 4
for PRMT5 and BRD7, and P<10
 3 for SUZ12) in
control WaC3CD5 cells, whereas binding of these
proteins was completely abolished in BRD7 knockdown
cells (Figure 6B). Interestingly, when we examined associ-
ation of PRMT5, SUZ12 and BRD7 with the RBL2
promoter, we discovered that their binding was enriched
7.5- to 10-fold (P<10
 4 for PRMT5, P=0.0018 for
SUZ12 and P<10
 3 for BRD7) in control cells, and
reduced signiﬁcantly in WaC3CD5/shBRD7 cells
(Figure 6C), implying that the presence of BRD7 is essen-
tial for PRMT5 and PRC2 recruitment. Interaction of
PRMT5, SUZ12 and BRD7 with the ST5 promoter was
unaffected in both control and test cell lines (Figure 6D),
further conﬁrming the importance played by BRD7 in
PRMT5 and SUZ12 recruitment to their target genes.
We have also monitored binding of PRMT5, SUZ12
and BRD7 to target promoters using a second and
distinct set of primers, and we have found similar results
(Supplementary Figure S3).
To assess if reduced recruitment of PRMT5 and PRC2
is accompanied by a decrease in H3R8, H4R3 and H3K27
methylation, we measured the levels of all three epigenetic
Figure 4. PRMT5, PRC2 and BRD7 co-exist on the same nucleosomes in the promoter region of ST7 and RBL2.( A–C) ChIP assays were
performed using cross-linked and MNase-treated chromatin from either JeKo or WaC3CD5 cells, and after nucleoprotein complexes were ﬁrst
immunoprecipitated (ﬁrst Ab) with the indicated antibodies, they were released in the presence of 20mM DTT. Next, a second round of immunopre-
cipitation (second Ab) was carried out using either PI, anti-PRMT5 or anti-SUZ12 antibodies, and real-time PCR was conducted as described in
Figure 3. This experiment was performed twice in triplicate.
Nucleic Acids Research, 2011,Vol.39, No. 13 5433marks at the ST7 and RBL2 promoters (Figure 6E and F).
ChIP analysis showed that methylation of histones H3R8
and H4R3 is highly enriched (7- to 13-fold, P<10
 4)a t
the ST7 promoter in control WaC3CD5 cells; however,
methylation of ST7 promoter histones H3 and H4 is dra-
matically reduced in WaC3CD5/shBRD7 cells
(Figure 6E). Similarly, when we checked the levels of
H3R8, H4R3 and H3K27 methylation at the RBL2
promoter in control and BRD7 knockdown cells, we
found that all three epigenetic marks were increased
7- to 8-fold (P<10
 4) in control WaC3CD5 cells. We
also discovered that while the levels of H3(Me2)R8 and
H3(Me3)K27 were decreased 2.4- to 2.8-fold (P<10
 4)i n
BRD7 knockdown cells, methylation of H4R3 was un-
affected (Figure 6F). No changes in histone methylation
were detected at the ST5 promoter (Figure 6G). Together,
these results demonstrate that BRD7 plays an important
role in PRMT5 and PRC2 recruitment, and that complete
removal of PRMT5- and PRC2-induced epigenetic marks
is important for efﬁcient transcriptional derepression of
their target genes.
Both RDM and KDM activities are recruited to PRMT5
and PRC2 target genes in BRD7 knockdown cells
Having found that symmetric methylation of H4(Me2)R3
is unaffected at the RBL2 promoter in BRD7 knockdown
cells, and knowing that there is only one other type II
protein arginine methyltransferase, PRMT7, capable of
H4R3 symmetric methylation (34), we tested if PRMT7
was associated with the RBL2 promoter in WaC3CD5
cells (Figure 7A). Our results showed that even though
PRMT7 is heavily recruited to other tumor suppressor
genes such as growth arrest speciﬁc (GAS) genes 1 and 2,
there was a complete lack of PRMT7 binding to RBL2,
suggesting that PRMT5 is the only histone arginine
methyltransferase involved in symmetric methylation of
H4R3 at the RBL2 promoter.
Because recruitment of PRMT5 is abolished in the
absence of BRD7, we reasoned that demethylation
of H4(Me2)R3 might be the limiting step for RBL2 tran-
scriptional derepression. Therefore, we sought to iden-
tify and study recruitment of enzymes capable of erasing
PRMT5-induced epigenetic marks. Recent work has
Figure 5. BRD7 knockdown triggers transcriptional derepression of ST7, but not RBL2.( A) Levels of BRD7 mRNA were measured by RT–PCR
using 1mg of total RNA from either control or BRD7 knockdown cell lines. Levels of 18S were used as an internal control. (B) RIPA extract (40mg)
from either control WaC3CD5 or BRD7 knockdown WaC3CD5 cell lines clones 1 and 2 were analyzed by western blotting using anti-BRD7,
anti-ST7, anti-RBL2, anti-ST5 or anti-b-ACTIN antibody. (C–E) Levels of ST7, RBL2 and ST5 mRNA were determined by real-time RT–PCR as in
Figure 5A. Graphs show normalized changes in expression for each gene relative to control WaC3CD5 cells using 18S as an internal control.
5434 Nucleic Acids Research, 2011,Vol.39, No. 13shown that demethylation of speciﬁc lysine residues is
intimately involved in transcriptional regulation, cellular
differentiation and disease (1,2,5). Similarly, there are
enzymes such as peptidylarginine deiminase 4 (PADI4),
which is capable of converting methylarginine to
citrulline (35,36), and Jumonji C domain-containing
protein 6 (JMJD6), which represents a novel class of
iron and 2-oxoglutarate-dependent dioxygenase en-
zymes, that can erase mono- and di-methylarginine
marks (37).
Figure 6. Recruitment of PRMT5 and PRC2 to ST7 and RBL2 promoters is reduced in BRD7 knockdown cells. (A) Whole-cell extracts (40mg)
from control or BRD7 knockdown cells were analyzed by western blotting using anti-PRMT5, anti-SUZ12 or anti-b-ACTIN. To detect PRMT5-
and PRC2-induced epigenetic marks, 5mg of hydrochloric acid-extracted histones were analyzed by western blotting using anti-H3(Me2)R8,
anti-H3(Me3)K27 or anti-H4(Me2)R3 antibody. Both anti-H3 and anti-H4 were used to show equal loading. Chromatin from control WaC3CD5
and BRD7 knockdown cells was immunoprecipitated with either control PI, anti-PRMT5, anti-SUZ12 or anti-BRD7 antibody, and the puriﬁed
DNA was analyzed by RT–PCR to determine enrichment of ST7 (B), RBL2 (C) and ST5 (D) promoter sequences. (E–G) Both arginine and lysine
methylation marks are reduced at the ST7, but not RBL2 promoter in BRD7 knockdown cells. ChIP assays were carried out using PI,
anti-H3(Me2)R8, anti-H4(Me2)R3 or anti-H3(Me3)K27 antibody, and target promoter sequences were detected as in Figure 3. The data points in
each graph show the average from two independent experiments.
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demethylates histones H3R2 and H4R3 (37), we checked
whether it is recruited to PRMT5 target genes
(Figure 7B–D). ChIP experiments showed that binding
of JMJD6 to the ST7 promoter was enhanced 3.3-fold
(P<10
 4) in BRD7 knockdown cells compared to
control WaC3CD5 cells (Figure 7B). When we evaluated
JMJD6 binding to the promoter regions of RBL2 and
control ST5, we found no signiﬁcant enrichment (1.3- to
1.5-fold, P<10
 3) (Figure 7C and D). We have shown
that recruitment of PRC2 and the levels of its epigenetic
mark are altered at the ST7 and RBL2 promoters in
BRD7 knockdown cells (Figure 6). Therefore, we
examined the binding status of two H3(Me3)K27-speciﬁc
demethylases, KDM6A/UTX and KDM6B/JMJD3, at
the ST7 and RBL2 promoters in both control and
BRD7 knockdown cells (Figure 7B and C). Our results
showed that binding of KDM6A/UTX and KDM6B/
JMJD3 is augmented 2.4- to 3.5-fold (P<10
 4) at the
ST7 promoter. Binding of both H3(Me3)K27-speciﬁc
demethylases differed at the RBL2 promoter in that only
KDM6A/UTX was bound to the promoter region
(1.9-fold enrichment, P<10
 4). To rule out the possibility
that differences in recruitment of demethylases arise from
changes in their protein levels, we performed western blot
analysis (Figure 7E). Expression of all three demethylases
was unaltered in control and BRD7 knockdown cells.
Taken together, these results indicate that both arginine
and lysine demethylases are involved in transcriptional
regulation of PRMT5 and PRC2 target genes.
DISCUSSION
Regulation of gene expression via histone
post-translational modiﬁcation has been the focus of
many studies, and understanding how various epigenetic
constellations impact gene transcription has become very
Figure 7. Arginine and lysine-speciﬁc demethylases are differentially recruited to the ST7 and RBL2 promoters. (A) PRMT7 is not involved in
transcriptional regulation of RBL2 in WaC3CD5 cells. Cross-linked chromatin from WaC3CD5 cells was immunoprecipitated using either PI or
anti-PRMT7 antibody, and GAS1, GAS2 and RBL2 promoter sequences were detected by real-time PCR using gene-speciﬁc primer sets and probes.
This experiment was repeated twice and real-time PCR was carried out in triplicate. ChIP assays were performed on cross-linked chromatin from
control WaC3CD5 and BRD7 knockdown cells using either PI, anti-JMJD6, anti-JMJD3 or anti-UTX antibody. Immunoprecipitated DNA was
ampliﬁed by real-time PCR to determine enrichment of each demethylase at the ST7 (B), RBL2 (C) and ST5 (D) promoters. (E) RIPA extracts
(40mg) from control WaC3CD5 and WaC3CD5/BRD7 knockdown cells were analyzed by western blotting using the indicated antibodies.
Anti-b-ACTIN was used to show equal loading.
5436 Nucleic Acids Research, 2011,Vol.39, No. 13important, especially as more histone marks are being
identiﬁed and implicated in both transcriptional activation
as well as repression. Studies by various groups have
shown that there are different molecular effectors
capable of recognizing and binding speciﬁc histones
marks; however, their mode of action remains obscure.
For instance, recent work by Xhemalce and Kouzaridez
showed that acetylation of H3K4, a mark generally
associated with gene activation, plays a major role in
the formation of repressive heterochromatin in
Schizosaccharomyces pombe by promoting a switch
in binding of HP1-like proteins to methylated H3K9
(38). This ﬁnding redeﬁnes the notion that there is a
strict code of histone modiﬁcations that speciﬁes a particu-
lar transcriptional outcome, and suggests that both acti-
vation and repression-speciﬁc marks could play dual roles
during gene transcription. Another example of the com-
plexity of mechanisms used to regulate chromatin struc-
ture comes from studies where WDR5, a component of
MLL complexes that binds methylated H3K4, can be
found in association with the H3(Me3)K27-speciﬁc
demethylase KDM6A/UTX (39), indicating that
histone-binding proteins can interact with both histone
methyltransferases as well as histone demethylases to
promote either gene activation or repression.
In this study, we have identiﬁed BRD7 as a component
of the PRMT5–hSWI–SNF complex, and using stable cell
lines that express epitope-tagged BRD7 complexes we
have shown that PRMT5 and hSWI–SNF subunits
co-purify with His-BRD7. We have also determined that
BRD7 interacts with speciﬁc hSWI–SNF subunits
including BRG1, BRM and BAF60, as well as PRMT5
and MEP50. Moreover, we have found that BRD7 can
also interact with components of the PRC2 repressor
complex in vitro. Our previous work showed that hSWI–
SNF-associated PRMT5 and its epigenetic marks are
enriched at the promoter region of ST7 and RBL2
tumor suppressor genes (23,31). Therefore, we
investigated the involvement of BRD7 and PRC2 in
PRMT5 target gene regulation. Both ChIP and
ChIP-re-ChIP analyses indicated that BRD7 and PRC2
co-localize with PRMT5 on ST7 and RBL2 target pro-
moters in vivo. To gain a better understanding of the
role played by BRD7 in ST7 and RBL2 transcriptional
regulation, we knocked down its expression and
measured the ST7 and RBL2 mRNA levels. Our ﬁndings
clearly show that reducing expression of BRD7 triggers
transcriptional derepression of ST7 as evidenced by the
increase in ST7 mRNA levels in BRD7 knockdown cells;
however, transcription of RBL2 was not affected even
though recruitment of both PRMT5 and PRC2 was
compromised in BRD7 knockdown cells.
To determine if lack of recruitment of PRMT5 and
PRC2 could result in a decrease in methylation of
histones H3 and H4, we used ChIP assays to measure
the levels of PRMT5 and PRC2-induced epigenetic
marks at the ST7 and RBL2 promoters in both control
as well as BRD7 knockdown cells. In accordance with the
real-time RT–PCR results (Figure 5C), we discovered that
H3(Me2)R8, H4(Me2)R3 and H3(Me3)K27 epigenetic
marks were completely removed from the ST7 promoter
region. When we checked the promoter region of RBL2,
we found that while methylation of H3R8 and H3K27 was
reduced in the absence of BRD7, symmetric methylation
of H4R3 was unaffected, raising the possibility that
another type II PRMT might be involved in RBL2 tran-
scriptional regulation. To date the only other type II
PRMT known for its ability to symmetrically methylate
H4R3 is PRMT7 (34). Therefore, we tested its association
with the RBL2 promoter in WaC3CD5 cells. Our results
indicated that even though PRMT7 was recruited to two
other tumor suppressor genes, GAS1 and GAS2, its asso-
ciation with the RBL2 promoter was not increased.
Since it has previously been shown that lysine methyla-
tion marks are removed by speciﬁc KDMs, and recent
studies have indicated that histone arginine methylation
can be erased by Jumonji C domain-containing RDMs, we
checked if there was altered recruitment of lysine and
arginine demethylases to the ST7 and RBL2 promoters.
ChIP analysis of H3(Me3)K27-speciﬁc demethylases
showed that while both KDM6A/UTX and KDM6B/
JMJD3 were efﬁciently recruited to the ST7 promoter,
only KDM6A/UTX was associated with RBL2.I n
addition, recruitment studies of the H4(Me2)R3-speciﬁc
demethylase JMJD6 revealed that its association with
the ST7 promoter is highly enriched in BRD7 knockdown
cells, while its binding to the RBL2 promoter is lacking in
these cells. These data are in complete agreement with the
ChIP results obtained using antibodies speciﬁc to
PRMT5- and PRC2-induced methylation marks
(Figure 7). Although it is not clear if binding of BRD7
to PRMT5 and PRC2 target genes precludes recruitment
of JMJD6, KDM6A/UTX and KDM6B/JMJD3, our
results provide important clues about the function of
BRD7 in recruiting PRMT5 and PRC2 repressors, and
suggest that transcriptional activation of repressed genes
does not only require release of enzymes involved in
inducing speciﬁc epigenetic marks, but also efﬁcient re-
cruitment of different combinations of lysine and
arginine-speciﬁc demethylases.
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